EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access

Advances in Tricyclic Compounds for the Treatment of Alzheimer's Disease

Yichun Shi, Xindan Liao, Guangjun Yu iD

ChemMedChem · 2026-07-29 · 21 (14)

DOI: 10.1002/cmdc.70384 ↗

At a glance

Übersichtsarbeit in ChemMedChem, published online on 2026-07-16. Written by Yichun Shi and 2 co-authors. Institution: Department of Medicinal Chemistry, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West Chi…. Major MEDLINE topics: Alzheimer Disease, Neuroprotective Agents, Cholinesterase Inhibitors. 252 references. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Alzheimer's disease (AD) is a complex neurodegenerative disorder involving interconnected pathological pathways, including cholinergic dysfunction, A β deposition, tau hyperphosphorylation, neuroinflammation, oxidative stress, and dysregulation of metal ion homeostasis. Recently, the “one drug, one target” paradigm has faced certain clinical limitations, driving a paradigm shift toward multi‐target therapeutic strategies. In this context, tricyclic scaffolds, characterized by rigid fused‐ring skeletons, excellent structural tunability, and favorable neuropharmacological properties, have emerged as promising scaffolds for developing multi‐target AD therapeutics. These molecules can interact with multiple AD‐related targets through stable π–π stacking and hydrophobic interactions. Some tricyclic scaffolds, such as tetrahydrocarbolines, share structural similarity with endogenous neurotransmitters, suggesting potential involvement in modulating cognitive and mood‐related pathways, along with favorable BBB permeability and neuro‐compatibility. Accordingly, this review begins by outlining the distinct pathological mechanisms underlying AD, followed by a summary of recent progress on tricyclic compounds, encompassing both single‐target and multi‐target‐directed molecules, with an emphasis on structure–activity relationships and mechanisms of action, aiming to offer new insights and strategies for combating this devastating disease.

Subjects

MeSH terms (MEDLINE)

Alzheimer DiseaseNeuroprotective AgentsCholinesterase InhibitorsHumansStructure-Activity RelationshipAnimalsMolecular StructureOxidative Stress

Author keywords

AChEAlzheimerAβmulti‐targetneuroinflammationoxidative stresspathogenesistricyclic scaffold

Substances

Neuroprotective AgentsCholinesterase Inhibitors

Authors and institutions

  • Department of Medicinal Chemistry, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West China School of Pharmacy, Sichuan University, Chengdu, China.
  • Institute of Materials, China Academy of Engineering Physics, Mianyang, Sichuan, China.

ORCID profiles: Guangjun Yu

Cite

APA

Shi, Y., Liao, X., & Yu, G. (2026). Advances in Tricyclic Compounds for the Treatment of Alzheimer's Disease. ChemMedChem, 21(14). https://doi.org/10.1002/cmdc.70384

Vancouver

Shi Y, Liao X, Yu G. Advances in Tricyclic Compounds for the Treatment of Alzheimer's Disease. ChemMedChem. 2026;21(14). doi:10.1002/cmdc.70384

BibTeX
@article{Shi2026,
  author = {Shi, Yichun and Liao, Xindan and Yu, Guangjun},
  title = {Advances in Tricyclic Compounds for the Treatment of Alzheimer's Disease},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {14},
  doi = {10.1002/cmdc.70384}
}
Start for free →